NDAORAL-21TABLET
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ORTHO-NOVUM 7/14-21 (ethinyl estradiol; norethindrone) by Johnson & Johnson. Approved for pregnancy. First approved in 1984.
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 7/14-21 is a biphasic oral contraceptive containing ethinyl estradiol and norethindrone in a 21-day tablet regimen. It prevents pregnancy by suppressing ovulation through combined estrogenic and progestagenic activity. This product targets women of reproductive age seeking hormonal contraception.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); brand defense and generic transition strategies will dominate team priorities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on ORTHO-NOVUM 7/14-21 places you in a sunset-phase product requiring defensive marketing and generic transition expertise rather than growth and innovation. Career advancement depends on skill in market segmentation, managed care negotiation, and portfolio evolution strategies to extend brand relevance.
Brand Manager
Worked on ORTHO-NOVUM 7/14-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.